

Australia & South Korea Diabetic Foot Ulcer Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis

Market Report | 2023-09-20 | 113 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The Australia & South Korea diabetic foot ulcer market is projected to reach US\$ 313.53 million by 2030 from US\$ 199.59 million in 2022; it is expected to grow at a CAGR of 5.8% from 2022 to 2030. The factors such as increasing prevalence of diabetes and related chronic wounds and the rise in geriatric population propel are expected to drive the Australia & South Korea diabetic foot ulcer market growth. Moreover, growing research activities to unveil novel wound treatment products is also expected to foster the Australia & South Korea diabetic foot ulcer market growth during the forecast period. However, the high cost of advanced wound care treatments may hinder the Australia & South Korea diabetic foot ulcer market growth.

Use of 3D Printing in Wound Care Management to Boost the Australia & South Korea Diabetic Foot Ulcer Market in Future

Skin tissue damage caused by various indications due to diabetes and vascular diseases significantly burdens the healthcare systems. 3D bioprinting is based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still nascent, 3D printing can potentially revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that promote angiogenesis for dermal regeneration. In addition, 3D bioprinting helps patch large wounds that are hard to heal with standard techniques. In July 2020, Startup Inventia Life Science Pty. Ltd. received two major funds from the Australian government to encourage the development of a robotic device that prints a patient's skin cells directly onto a burn or wound. Thus, the use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the diabetic foot ulcer market in the coming years.

Thus, such advancements are expected to foster diabetic foot ulcer and enhance the Australia & South Korea diabetic foot ulcer market growth in the coming years.

The Australia & South Korea diabetic foot ulcer market is segmented on the basis of ulcer type, treatment type, infection severity,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

end user, and country. Based on ulcer type, the Australia & South Korea diabetic foot ulcer market is segmented into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment held the largest share of the market in 2022, and it is anticipated to register the highest CAGR during the forecast period. Based on treatment type, is segmented into advanced wound care dressings, biologics, and therapy device. The advanced wound care dressings segment held the largest market share in 2022. The biologics segment is anticipated to register the highest CAGR of 6.4% during 2022-2030. Advanced wound care dressings are further segmented as alginate dressings, hydrofiber dressings, foam dressings, collagen dressings, film dressings, and others. Only standard-of-care therapy is often not sufficient to heal diabetic foot ulcer wounds and requires the subsequent or simultaneous application of adjuvant wound therapies, including biological skin substitutes. Biologics are developed from natural sources, including humans, animals, and microorganisms. Cell-based biological substitutes are used particularly for the treatment of wounds. Based on infection severity, is categorized into moderate, mild, and severe. The moderate segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022-2030. Based on end user, the market is segmented into ambulatory surgical centers, hospitals, and home care. The hospital segment held the largest market share in 2022 and the same segment is anticipated to register the highest CAGR during 2022-2030.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), International Working Group on the Diabetic Foot (IWGDF), US Food and Drug Administration (FDA), and Ministry of Food and Drug Safety (MFDS) are among some of the primary and secondary sources referred to while preparing the report on the Australia & South Korea diabetic foot ulcer market.

Table of Contents:

TABLE OF CONTENTS

- 1. Introduction
 - 1.1 The Insight Partners Research Report Guidance
 - 1.2 Market Segmentation
- 2. Executive Summary
 - 2.1 Key Insights
- 3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
- 4. Australia & South Korea Diabetic Foot Ulcer Market - Market Landscape
 - 4.1 Overview
 - 4.1.1 Australia & South Korea PEST Analysis
 - 4.2 Ecosystem Analysis
 - 4.3 Classification Systems of Diabetic Foot Ulcer
 - 4.3.1 SINBAD (Site, Ischemia, Neuropathy, Bacterial infection, Depth)
 - 4.3.2 PEDIS (Perfusion, Extent, Depth, Infection, Sensation)
 - 4.3.3 UT (University of Texas)
 - 4.3.4 WIFI (Wound, Ischemia, and Foot Infection)
 - 4.3.5 Meggitt-Wagner System
 - 4.3.6 Others
 - 4.4 Australian Guidelines on Wound Classification of Diabetes-Related Foot Ulcers
 - 4.4.1 Overview
 - 4.5 Number of Hospitalizations for DFU in Australia and South Korea, 2022
- 5. Australia & South Korea Diabetic Foot Ulcer Market - Country Analysis
 - 5.1 Key Market Drivers:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1 High Prevalence of Diabetes and Related Chronic Wounds
- 5.1.2 Surge in Geriatric Population
- 5.2 Market Restraints
 - 5.2.1 High Cost of Advanced Wound Care Treatments
- 5.3 Market Opportunities
 - 5.3.1 Growing Research Activities to Unveil Novel Wound Treatment Products
- 5.4 Future Trends
 - 5.4.1 Use of 3D Printing in Wound Care Management
- 5.5 Impact Analysis:
- 6. Australia & South Korea Diabetic Foot Ulcer Market - Country Analysis
 - 6.1 Australia & South Korea Diabetic Foot Ulcer Market Revenue Forecast and Analysis
- 7. Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - by Treatment Type
 - 7.1 Overview
 - 7.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, by Treatment Type 2022 & 2030 (%)
 - 7.3 Advanced Wound Care Dressings
 - 7.3.1 Overview
 - 7.3.2 Advanced Wound Care Dressings: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.3 Alginate Dressings
 - 7.3.3.1 Overview
 - 7.3.3.2 Alginate Dressings: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.4 Hydrofiber Dressings
 - 7.3.4.1 Overview
 - 7.3.4.2 Hydrofiber Dressings: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.5 Foam Dressings
 - 7.3.5.1 Overview
 - 7.3.5.2 Foam Dressings: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.6 Collagen Dressing
 - 7.3.6.1 Overview
 - 7.3.6.2 Collagen Dressing: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.7 Film Dressing
 - 7.3.7.1 Overview
 - 7.3.7.2 Film Dressing: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.3.8 Other Dressings
 - 7.3.8.1 Overview
 - 7.3.8.2 Other Dressing: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.4 Biologics
 - 7.4.1 Overview
 - 7.4.2 Biologics: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.4.3 Growth Factors
 - 7.4.3.1 Overview
 - 7.4.3.2 Growth Factors: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.4.4 Skin Graft
 - 7.4.4.1 Overview
 - 7.4.4.2 Skin Graft: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 7.5 Therapy Device
 - 7.5.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.5.2 Therapy Device: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 7.5.3 Negative Pressure Wound Therapy
 - 7.5.3.1 Overview
 - 7.5.3.2 Negative Pressure Wound Therapy: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 7.5.4 Ultrasound Therapy
 - 7.5.4.1 Overview
 - 7.5.4.2 Ultrasound Therapy: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 8. Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Ulcer Type
 - 8.1 Overview
 - 8.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Ulcer Type 2022 & 2030 (%)
 - 8.3 Neuropathic Ulcers
 - 8.3.1 Overview
 - 8.3.2 Neuropathic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 8.4 Ischemic Ulcers
 - 8.4.1 Overview
 - 8.4.2 Ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 8.5 Neuro-ischemic Ulcers
 - 8.5.1 Overview
 - 8.5.2 Neuro-ischemic Ulcers: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 9. Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Infection Severity
 - 9.1 Overview
 - 9.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By Infection Severity 2022 & 2030 (%)
 - 9.3 Mild, Moderate, and Severe
 - 9.3.1 Overview
 - 9.3.2 Mild: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 9.3.3 Moderate: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 9.3.4 Severe: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 10. Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By End User
 - 10.1 Overview
 - 10.2 Australia & South Korea Diabetic Foot Ulcer Market Revenue Share, By End User 2022 & 2030 (%)
 - 10.3 Hospitals
 - 10.3.1 Overview
 - 10.3.2 Hospitals: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.4 Ambulatory Surgical Centers
 - 10.4.1 Overview
 - 10.4.2 Ambulatory Surgical Centers: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
 - 10.5 Home Care
 - 10.5.1 Overview
 - 10.5.2 Home Care: Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (US\$ Million)
- 11. Australia & South Korea Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - Geographic Analysis
 - 11.1 Australia: Diabetic Foot Ulcer Market Revenue and Forecast to 2030
 - 11.1.1 Overview
 - 11.1.1.1 Australia: Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (USD Million)
 - 11.1.1.1.1 Australia: Diabetic Foot Ulcer Market, by Type, 2030 (USD Million)
 - 11.1.1.1.2 Australia: Diabetic Foot Ulcer Market, by Treatment Type, 2030 (USD Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.1.1.2.1 Australia: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
- 11.1.1.1.2.2 Australia: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
- 11.1.1.1.2.3 Australia: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
- 11.1.1.1.3 Australia: Diabetic Foot Ulcer Market, by Infection Severity, 2030 (USD Million)
- 11.1.1.1.4 Australia: Diabetic Foot Ulcer Market, by End User, 2030 (USD Million)
- 11.1.1.2 South Korea: Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (USD Million)
 - 11.1.1.2.1 South Korea: Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 (USD Million)
 - 11.1.1.2.2 South Korea: Diabetic Foot Ulcer Market, by Type, 2030 (USD Million)
 - 11.1.1.2.3 South Korea: Diabetic Foot Ulcer Market, by Treatment Type, 2030 (USD Million)
 - 11.1.1.2.3.1 South Korea: Diabetic Foot Ulcer Market, by Advanced Wound Care Dressings, 2030 (USD Million)
 - 11.1.1.2.3.2 South Korea: Diabetic Foot Ulcer Market, by Biologics, 2030 (USD Million)
 - 11.1.1.2.3.3 South Korea: Diabetic Foot Ulcer Market, by Therapy Device, 2030 (USD Million)
 - 11.1.1.2.4 South Korea: Diabetic Foot Ulcer Market, by Infection Severity, 2030 (USD Million)
 - 11.1.1.2.5 South Korea: Diabetic Foot Ulcer Market, by End User, 2030 (USD Million)
- 12. Pre and Post COVID-19 Impact
 - 12.1 Pre and Post COVID-19 Impact
- 13. Australia & South Korea Diabetic Foot Ulcer Market - Industry Landscape
 - 13.1 Overview
 - 13.2 Growth Strategies in the Australia & South Korea Diabetic Foot Ulcer Market
 - 13.3 Inorganic Growth Strategies
 - 13.3.1 Overview
 - 13.4 Organic Growth Strategies
 - 13.4.1 Overview
- 14. Company Profiles
 - 14.1 Convatec Group Plc
 - 14.1.1 Key Facts
 - 14.1.2 Business Description
 - 14.1.3 Products and Services
 - 14.1.4 Financial Overview
 - 14.1.5 SWOT Analysis
 - 14.1.6 Key Developments
 - 14.2 3M Co
 - 14.2.1 Key Facts
 - 14.2.2 Business Description
 - 14.2.3 Products and Services
 - 14.2.4 Financial Overview
 - 14.2.5 SWOT Analysis
 - 14.2.6 Key Developments
 - 14.3 Coloplast AS
 - 14.3.1 Key Facts
 - 14.3.2 Business Description
 - 14.3.3 Products and Services
 - 14.3.4 Financial Overview
 - 14.3.5 SWOT Analysis
 - 14.3.6 Key Developments
 - 14.4 Smith & Nephew Plc
 - 14.4.1 Key Facts

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 B. Braun SE
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 Molnlycke Health Care AB
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 MiMedx Group Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 URGO MEDICAL Australia Pty Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 Medline Industries LP
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
- 14.10 Organogenesis Inc.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Australia & South Korea Diabetic Foot Ulcer Market Size and Forecasts (2020 - 2030), Country Share, Trends, and Growth Opportunity Analysis

Market Report | 2023-09-20 | 113 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com